Skip to Main Content



The high prevalence of movement disorders throughout the world means that a large number of people are afflicted with diseases that are characterized by involuntary movements (e.g. essential tremor, Parkinson’s disease, tics, dystonia, restless legs syndrome). Clinical research in the Movement Disorders division takes on a number of forms, including research on the clinical features, epidemiology, genetics, neuroimaging characteristics, and pathological mechanisms of these disorders. All of the clinical research in the division involves the participation of patients who have involuntary movements. The bulk of current clinical research relates to Parkinson’s disease. Clinical studies in the division also extend to the area of experimental therapeutics, where a number of treatment trials are currently underway.


Measuring Synaptic Density in Parkinson's Disease with SV2A PET Imaging

Synaptic changes play a critical role in the pathogenesis and progression of PD. This study investigates the changes in synaptic density in individuals with PD by using positron emission tomography (PET) imaging with 11C-UCB-J, a recently developed PET radiotracer that binds to the synaptic vesicle glycoprotein, 2A. Contact principal investigator David Matuskey, MD for more information.

Yale Parkinson’s and REM Behavior Disorders Research Study

We are seeking patients who have been diagnosed with Parkinson’s disease in the past 10 years and persons with REM sleep behavior disorder (with or without Parkinson’s disease) to participate in a research study at the Yale School of Medicine. Our research group in Yale’s Department of Neurology, under the leadership of Dr. David Hafler is conducting a clinical research study funded by Aligning Science Against Parkinson’s (ASAP) to determine the role played by the immune system in the initiation and evolution of the pathological processes of REM sleep behavior disorder and Parkinson’s disease. Our hope is to uncover information that will ultimately allow us to design a clinical trial to use immunosuppressing medicines to prevent or slow progression of Parkinson disease. This observational, non-treatment trial is the first step.

If you decide to participate in the study, you will be invited to Yale’s clinical research unit in New Haven, Connecticut to undergo clinical assessment and for the collection of biological samples including blood, stool, and spinal fluid. In addition, you may be asked to undergo a brain scan. Please email our research coordinator, Kara Mead, or call her at 203-785-2285 if you are interested in learning more about our study.

Clinical Trials